Skip to main content

Drug Interactions between amphotericin b lipid complex and flucytosine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

flucytosine amphotericin B lipid complex

Applies to: flucytosine and amphotericin b lipid complex

MONITOR: Concomitant use of amphotericin B may potentiate the toxicity of flucytosine. The exact mechanism of interaction is unknown but may involve increased cellular uptake of flucytosine or impairment of its renal excretion. The risk of gastrointestinal, hepatic, and hematologic toxicity may be increased.

MANAGEMENT: Caution is advised if flucytosine must be used in patients who are receiving treatment with amphotericin. Blood levels should be monitored and the dose or dosing interval should be adjusted to maintain flucytosine concentrations below 100 mcg/mL.

References (5)
  1. Kauffman CA, Frame PT (1977) "Bone marrow toxicity associated with 5-fluorocytosine therapy." Antimicrob Agents Chemother, 11, p. 244-7
  2. Bryan CS, McFarland JA (1978) "Cryptococcal meningitis: fatal marrow aplasia from combined therapy." JAMA, 239, p. 1068-9
  3. (2022) "Product Information. Fungizone (amphotericin B)." Apothecon Inc
  4. (2002) "Product Information. Ancobon (flucytosine)." Roche Laboratories
  5. "Product Information. Abelcet (amphotericin B lipid complex)." Liposome Company Inc, The

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Antifungal agents

Therapeutic duplication

The recommended maximum number of medicines in the 'antifungal agents' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'antifungal agents' category:

  • amphotericin b lipid complex
  • flucytosine

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer